| 引用本文: | 费保莹,吴人照,陈璇,朱佳杰,戴关海,梅茜钰,柴可群.益胃饮对MNNG诱导的大鼠慢性萎缩性胃炎和胃癌的疗效及机制[J].中国现代应用药学,2024,41(16):1-8. |
| Fei Baoying,Wu Renzhao,Chen Xuan,Zhu Jiajie,Dai Guanhai,Mei Xiyu,Chai Kequn.Study on the effect and mechanism of Yiwei Decoction in the treatment of MNNG-induced chronic atrophic gastritis rats and gastric cancer rats[J].Chin J Mod Appl Pharm(中国现代应用药学),2024,41(16):1-8. |
|
| 摘要: |
| 目的 探究益胃饮对慢性萎缩性胃炎(CAG)和胃癌的治疗作用及其潜在分子机制。方法 采用N-甲基-N’-硝基-亚硝基胍(MNNG)不同周期灌胃分别诱导大鼠慢性萎缩性胃炎和胃癌模型，益胃饮干预后观察其疗效；结合高通量测序和RT-qPCR检测MNNG诱导肿瘤大鼠胃组织及血液中的转录水平差异。结果 益胃饮显著改善MNNG诱导的大鼠慢性萎缩性胃炎和肠化生，显著降低MNNG诱导的大鼠胃十二指肠瘤块重量。高通量测序和RT-qPCR验证结果显示，胃组织中Vcan、BGIG10116_32332、rno-miR-542-3p和血清中rno-miR-363-3p的表达在MNNG诱导后有显著升高，而益胃饮可以明显逆转这些现象。同时益胃饮可以不同程度地降低VEGFR、HER-2等胃癌治疗靶点的表达水平。结论 益胃饮具有治疗MNNG诱导的慢性胃萎缩和肠化生等胃癌前病变的显著疗效，并能进一步抑制MNNG诱导的大鼠胃十二指肠肿瘤进展，其药效机制可能是通过抑制胃部vcan、lncRNA BGIG10116_32332和rno-miR-542-3p的过表达，及抑制血液中rno-miR-363-3p的过表达。 |
| 关键词: 益胃饮 治未病 慢性萎缩性胃炎 胃癌前病变 胃癌 分子机制 |
| DOI： |
| 分类号:R284.1；R917.101?????? |
| 基金项目:国家自然科学基金项目(81973654、81703789)，浙江省中医药（中西医结合）重点学科建设项目（2017-XK-A24），浙江省中西医结合肿瘤防治技术研究重点实验室（2011F10043） |
|
| Study on the effect and mechanism of Yiwei Decoction in the treatment of MNNG-induced chronic atrophic gastritis rats and gastric cancer rats |
|
Fei Baoying, Wu Renzhao, Chen Xuan, Zhu Jiajie, Dai Guanhai, Mei Xiyu, Chai Kequn
|
|
Zhejiang Academy of Traditional Chinese Medicine
|
| Abstract: |
| OBJECTIVE To explorer the effect and potential molecular mechanisms of Yiwei Decoction on chronic atrophic gastritis (CAG) and gastric cancer. METHODS N-methyl-N’-nitro-N-nitrosoguanidine (MNNG) was used to induce the model of CAG/gastric precancerous lesions and gastric cancer in rats. high-throughput sequencing technology and RT-qPCR were used to detect the change of transcriptome in stomach and blood of MNNG-induced tumor rats. RESULTS Yiwei Decoction significantly ameliorated the MNNG-induced chronic atrophic gastritis and intestinal metaplasia in rats, and significantly reduced the weight of tumor at gastroduodenal junction. Induction of MNNG obviously increased the mRNA level of Vcan, BGIG10116_32332 and rno-miR-542-3p in rat stomach and rno-miR-363-3p in rat serum, while Yiwei Decoction reversed these change. Moreover, Yiwei Decoction could slightly reduce the expression of gastric cancer therapeutic targets including VEGFR and HER-2. CONCLUSION Yiwei Decoction was effective in the treatment of MNNG-induced chronic atrophic gastritis and intestinal metaplasia; furthermore, early intervention of Yiwei Decoction could significantly inhibit the weight of gastroduodenal tumor. The engaged mechanism might be through inhibiting the over-expression of Vcan, BGIG10116_32332 and rno-miR-542-3p in stomach and reducing the over-expression of rno-miR-363-3p in blood. |
| Key words: yiwei decoction preventive treatment chronic atrophic gastritis precancerous lesions of gastric cancer gastric cancer molecular mechanisms |
